For example, coupling CRISPRa screening with scRNA sequencing revealed T cell activation and states, which could inform the design of immunotherapies.[51] The nanoparticles co‐loaded with CRISPR/Cas9 (targeting CDK5 gene) and paclitaxel could effectively inhibit tumor growth.[52] The dCasRx‐SINEB2 technology was used for translational control of targeted mRNA by coupling the sgRNA of a catalytically inactive CasRx to an integrated SINEB2 domain of uchl1 lncRNA.[53] We verified that the c‐Src/NF‐κB pathway regulates LIST expression by activating the transcription factor P65. The gene discussed is UCHL1; the disease is neoplasm.